-
When counseling a woman on when to start her first pack of oral contraceptives (OCs), what is your strategy for pill initiation? Most participants in the 2007 Contraceptive Technology Update Contraception Survey say they are using the Quick Start method.
-
A year ago, the introduction of the human papillomavirus (HPV) vaccine was being hailed as a major public health success story.
-
Your next patient is a young mother of three who is looking for long-term, effective contraception. She says she is not ready to consider tubal sterilization. What methods can you offer her?
-
Your next patient says she is interested in using Lybrel, the new continuous-use oral contraceptive (OC). What should you tell her about this form of birth control?
-
Researchers have launched a clinical safety trial of VivaGel (SPL7013), a topical vaginal microbicide, for potential use in preventing the sexual transmission of HIV.
-
If your practice includes older women, what is your approach in discussing risks for HIV? It's time to address such issues. Results of a new study indicate that older women may not be interested in being tested for HIV, despite having significant risk factors for lifetime exposure.
-
New research released on Lybrel, the first dedicated continuous use oral contraceptive (OC) (Wyeth Pharmaceuticals; Collegeville, PA), underscores the safety of the new drug.
-
How many women in your family planning facility may be missing a needed Pap smear? Check your numbers: One-fourth of uninsured U.S. women between the ages of 18-64 report not having had a Pap smear within the last three years of a government-issued survey.
-
With findings suggesting that male circumcision reduces risk of HIV acquisition for men, researchers now are turning attention on circumcision's impact on acquisition of sexually transmitted disease (STD) for women.
-
Results from a new international meta-analysis study of Gardasil (Merck & Co.; Whitehouse Station, NJ), the cervical cancer vaccine, indicate the shot is nearly 100% effective against the two types of the human papillomavirus (HPV) responsible for most cases of cervical cancer.
